Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
Sign Up to like & getrecommendations! Published in 2020 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics12121180
Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US… read more here.
Keywords: monoclonal antibodies; drug drug; anti migraine; drug ... See more keywords